Navigation Links
XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
Date:9/10/2007

able for replay by calling +1-888-203-1112 (in the United States), +1-719-457-0820 (outside the United States), replay passcode 2040477, for a period of 45 days after the call.

ABOUT DIABETIC NEUROPATHIC PAIN

Diabetic neuropathic pain is a chronic pain condition resulting from damage to nerves in patients with diabetes. Diabetic neuropathic pain, which manifests itself primarily in the feet, can often be debilitating thus preventing patients from carrying out their normal day-to-day activities. In the United States, it is estimated that 4.5 million patients with diabetes suffer from diabetic neuropathic pain. Diabetic neuropathic pain is the largest segment in the rapidly growing market for neuropathic pain drugs. This market was estimated at $1.8 billion in 2005, and is expected to grow to $5.5 billion by 2015. Only two oral drugs have been approved to date by the FDA for the treatment of diabetic neuropathic pain (Eli Lilly's Cymbalta(R), an SNRI, and Pfizer's Lyrica(R)); however, the response rates to these drugs are limited. Consequently, millions of patients remain without adequate treatment options and seek new drugs that could provide better relief for their chronic pain.

ABOUT THE SNRI DRUG CLASS

Serotonin and Norepinephrine Reuptake Inhibitors (SNRI's) are drugs that increase the levels of serotonin and norepinephrine in the brain, thus blocking pain signals. SNRI is a proven drug class in diabetic neuropathic pain as well as Major Depressive Disorder. One SNRI (Eli Lilly's Cymbalta(R)) is already approved for the treatment of diabetic neuropathic pain, while a second SNRI (Wyeth's Effexor(R)) has demonstrated efficacy in treatment of diabetic neuropathic pain in large, randomized and placebo-controlled studies. Both Cymbalta(R) and Effexor(R) are also approved for depression. A third SNRI (Cypress' Milnacipran(R)) recently demonstrated efficacy in a Phase III trial in a related neuropathic pain indication (fibromyalgia), providing f
'/>"/>

SOURCE XTL Biopharmaceuticals Ltd
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
2. Protocol for RNA Isolation Using TRIzol Reagent with Phase Lock Gel-Heavy
3. Easy preparation of total RNA from cultured cells with TRIzol and Eppendorf Phase Lock Gel
4. Identification of cells in S phase using the Cell Proliferation Fluorescence Kit and IN Cell Analyzer 1000
5. Direct Monitoring of Solid-Phase Peptide Synthesis by MALDI-TOF MS
6. Separation and Quantitation of R and S Enantiomers using Normal Phase Chromatography on an API 3000 LC/MS/MS System
7. Identification of Phase I and Phase II Metabolites of Buspirone on the Q TRAP LC/MS/MS System
8. Strategies to Identify and Confirm Phase I Metabolites of Glyburide Using the 4000 Q TRAP System
9. ANALYSIS OF AMINO ACIDS BY REVERSED PHASE CHROMATOGRAPHY WITH PRECOLUMN DERIVATISATION AND UV/VISIBLE DETECTION
10. Novel Bonding Chemistry Imparts Enhanced Polar Selectivity to TSK-GEL ODS-100V Reversed Phase Columns
11. Mobile Phase Optimization for the Analysis of an Antibody-Based Fusion Protein and Aggregates using a TSKgel Super SW3000 Size-Exclusion Column

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...SHANGHAI,Nov.24/PRNewswire-Asia/--ShanghaiBiolaxya...n(SFDA)hasapprovedthe,investigationalnewdrugapplic...vativeinsulinformulationtotreatdiabetes.ThisIND,ap...lstudy. , Diabetesisadisordercharacteristicof...sofdiabetesoftenresultinseveremicro-and,macro-vasc...
(Date:11/24/2009)...TSXVENTURE:HTL , TORONTO,Nov.24/PRNewswire-Fi...ottoCapitalInc.,aleadingproviderofadvancedlasersys...tyclinicmarkets,todayreportedoperationalandfinanci..., ,Q32009Highlights,-Revenuewas$1.46millioncompa...6.3percentcomparedwith66.1percentinQ3,2008,-Netlos...
(Date:11/24/2009)...BOZEN,Italy,November24/PRNewswire/--HealthRobotics...turewithagroupofselected,investors.Thisrecentlyfor...lthRoboticsCanada,Inc.andwillmarket,install,andsup...chincludesthe,revolutionaryproductofferingsi.v.STA...nadaInc.willalsoprovideassistanceonan"asneeded,bas...
(Date:11/23/2009)...LAKE CITY, Nov. 23, 2009 In a provocative new stu...ing carbon dioxide emissions the major cause of g...ld,s economy collapses or society builds the equiv... "It looks unlikely that there will be any substa...cceleration in carbon dioxide emission rates," say...
Breaking Biology Technology:Biolaxy Secures IND Approval for Oral Insulin 2Hamilton Thorne announces third quarter results 2Hamilton Thorne announces third quarter results 3Hamilton Thorne announces third quarter results 4Hamilton Thorne announces third quarter results 5Hamilton Thorne announces third quarter results 6Hamilton Thorne announces third quarter results 7Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2Is global warming unstoppable? 2Is global warming unstoppable? 3Is global warming unstoppable? 4
... Holidays often induce stress,but caring for child...ditional layer of pressure. Parents and caregivers...participate in live Web chats with,diabetes specia...ild,s,diabetes during the holidays, find social su... Fit Food, booklet for tips on healthy eating. Th...
...edarex, Inc.,(Nasdaq: MEDX ) today announced that...s Board of Directors to serve as a director on Med...n is President and CEO of Titan Pharmaceutical, In... the American Stock Exchange.,Prior to joining Tit... and,Development for Bayer Schering Pharma and a m...
...et earnings increase by almost 75% and by 52% ... All amounts are in U.S. dollars, ...m Innovations Inc.,(TSX: ATB) today announced that... quarter ended September 30, 2007, up 37.7% from U...06. Earnings before interest, taxes,depreciation a...
Other Biology Technology:New Web Site Tools Help Alleviate Stress Associated with Caring for Children with Diabetes During the Holidays 2Medarex Announces Election of Marc Rubin as New Board Member 2Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007 2Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007 3Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007 4Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007 5Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007 6Atrium Announces a Significant Increase in Revenues and Earnings for the Third Quarter of 2007 7
(Date:11/23/2009)...w study by the Wildlife Conservation Society says ...amp in the Republic of Congopart of the "mother lo...yearare becoming increasingly threatened by growin...ommends protection of the swamp forests adjacent t... after recent surveys confirmed that high densitie...
(Date:11/23/2009)...PAIGN, Ill. A new study provides "incontrovertibl...ba on the island of Sumatra about 73,000 years ago...s from the epicenter, researchers report. , The ...of ash into the atmosphere, leaving a crater (now ...ometers long and 35 kilometers wide. Ash from the ...
(Date:11/23/2009)...N, WI, November 16, 2009 -- A USDOE and USDA study... idle cropland, and cropland pasture could be conv...nial grasses, such as switchgrass, from which biom...ock. Economically viable production of a perennial...es of biomass are removed annually is expected to ...
Breaking Biology News(10 mins):A year after discovery, Congo's 'mother lode' of gorillas remains vulnerable 2Supervolcano eruption -- in Sumatra -- deforested India 73,000 years ago 2Switchgrass produces biomass efficiently 2NSF provides 243 4 million to study climatically important Agulhas Current 9052 1NSF provides 243 4 million to study climatically important Agulhas Current 9052 2Prostate screening studies reviewed in European Urology July issue 50307 1Prostate screening studies reviewed in European Urology July issue 50307 2Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Greece by SpePharm 50303 1Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Greece by SpePharm 50303 2Access Pharmaceuticals Announces Commercial Launch of MuGard 28TM 29 in Greece by SpePharm 50303 3
... MIT Holding, Inc. (OTCBB: MITD), in collaboration...e successfully tested prototype designs of the pat...ce is designed to stop the development of pathogen...dly diseases such as malaria, dengue fever, and We...e available in countries where such diseases are a...
...lobal STM publishers, has entered a publishing par...RF) for the journal Estuaries and Coasts. Appeari...e in promoting research on and management of estua...ished at Springer will be February 2008. The part...07 Conference from 4-8 November 2007, in Providenc...
...honey bee queen appears to be determined to a larg...ne bees. , That is what research by scientists i...r for Behavioral Biology at North Carolina State U...post-doctoral research associate; Dr. David Tarpy,...e Extension apiculturist; and Dr. Christina Grozin...
Other Biology News:MIT Holding, Georgia Southern University, and MEVLABS successfully test the PROVECTOR 2Estuarine Research Federation chooses Springer as publishing partner 2For honey bee queens, multiple mating makes a difference 2For honey bee queens, multiple mating makes a difference 3
...tween the 500 l and 4 ml centrifugal concentrators...vaspin products with low internal surface and memb... solutions. ,Available with a choice of PES, Ce...e highest flexibility for process optimisation. ,...
Goat Anti-Human Lipocalin 2 Antibody, Unconjugated from Novus Biologicals
...ated proteins both of which function in tumor supp...dependent manner. p14^ARF^ binds to mdm2 and promo...for mdm2 modification and concurrent p53 stabiliza...ed by the exon 1Beta-encoded N-terminal domain of ...
Corning Culture Flask, 150 cm2, Tc-Treated, Angled Neck, Phenolic-Style, Sterile from Sigma-Aldrich
Biology Products: